Management of Metastatic Hormone-Sensitive Prostate Cancer

William K. Oh, MD


June 26, 2020

For decades, standard care of metastatic hormone-sensitive prostate cancer (mHSPC) has relied on androgen deprivation therapy (ADT). Since 2015, a series of randomized trials has demonstrated significant improvements in survival. Four drugs are currently approved to treat mHSPC: docetaxel, abiraterone acetate, enzalutamide, and apalutamide.

Dr William K. Oh, chief of the Department of Hematology-Oncology at the Tisch Cancer Institute of Mount Sinai Health System, reviews current recommendations for the treatment of mHSPC on the basis of a patient's clinical factors, medication side effects, and disease volume.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.